Systems Improvement Conference - Fatal Breath: Delays in Recognition and Treatment of Sickle Cell Crisis
About this Event
Department of Medicine Systems Improvement Conference - Fatal Breath: Delays in Recognition and Treatment of Sickle Cell Crisis
The DOM Systems Improvement Conference is a UCG-certified collaborative case review (CCR) in which members of a multidisciplinary health care team engage in objective, nonjudgmental review of adverse outcomes and commit to systemic process change. All participants are reminded this is a privileged and confidential meeting, subject to quality review protections at University of Colorado Hospital and in the State of Colorado.
Join us Virtually via Zoom.
Learning Objectives:
- Define moral injury and develop a conceptual model for how it relates to moral distress and burnout.
- Explore the prevalence of moral injury among healthcare workers and examine tools to measure it.
- Devise strategies to cultivate a holistic approach to prevent and counter moral injury.
Accreditation & Designation Statement: The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Colorado School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure Statement: All of the planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationships to disclose with ineligible companies, whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.